Drug intelligence / Profile preview

GGW101

Development stage: Unknown
Lead developer: MingMed Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

GGW101 (Lirucitinib) is a small molecule Janus kinase (JAK) inhibitor developed for veterinary use, specifically for the treatment of canine pruritus—a condition characterized by an unpleasant skin sensation that provokes scratching. The drug targets immune-mediated pathways involved in pruritus and has received regulatory approval in China as a Class I New Veterinary Drug for this indication. It was approved by the Ministry of Agriculture and Rural Affairs of China in October 2024 following successful clinical development, including a Phase I trial initiated in March 2022[3].

Other names: Lirucitinib

Targets

JAK (Janus kinase family)

Beyond the preview

Go deeper on GGW101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GGW101.

Explore the full profile